KURN Stock Overview
A biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 16.30 |
| 52 Week High | CHF 16.60 |
| 52 Week Low | CHF 1.76 |
| Beta | 1 |
| 11 Month Change | 36.75% |
| 3 Month Change | 104.01% |
| 1 Year Change | 757.89% |
| 33 Year Change | 557.26% |
| 5 Year Change | 955.02% |
| Change since IPO | -45.67% |
Recent News & Updates
Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Recent updates
Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Shareholder Returns
| KURN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 26.4% | 11.2% | 1.3% |
| 1Y | 757.9% | 52.3% | 7.9% |
Return vs Industry: KURN exceeded the Swiss Biotechs industry which returned 51.7% over the past year.
Return vs Market: KURN exceeded the Swiss Market which returned 8.8% over the past year.
Price Volatility
| KURN volatility | |
|---|---|
| KURN Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: KURN's share price has been volatile over the past 3 months.
Volatility Over Time: KURN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 106 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| KURN fundamental statistics | |
|---|---|
| Market cap | CHF 608.03m |
| Earnings (TTM) | -CHF 8.89m |
| Revenue (TTM) | CHF 52.54m |
11.6x
P/S Ratio-68.4x
P/E RatioIs KURN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURN income statement (TTM) | |
|---|---|
| Revenue | CHF 52.54m |
| Cost of Revenue | CHF 6.43m |
| Gross Profit | CHF 46.11m |
| Other Expenses | CHF 55.00m |
| Earnings | -CHF 8.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 87.77% |
| Net Profit Margin | -16.91% |
| Debt/Equity Ratio | 0% |
How did KURN perform over the long term?
See historical performance and comparison